Recombinant human PPAR-β/δ ligand-binding domain is locked in an activated conformation by endogenous fatty acids

被引:64
作者
Fyffe, SA
Alphey, MS
Buetow, L
Smith, TK
Ferguson, MAJ
Sorensen, MD
Björkling, F
Hunter, WN [1 ]
机构
[1] Univ Dundee, Sch Life Sci, Div Biol Chem & Mol Microbiol, Dundee DD1 5EH, Scotland
[2] LEO Pharma, Med Chem Res, DK-2750 Ballerup, Denmark
基金
英国惠康基金;
关键词
crystal structure; fatty acid; ligand-binding domain; mass spectrometry; nuclear receptor;
D O I
10.1016/j.jmb.2005.12.047
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
High-resolution crystallographic structures of recombinant human peroxisome proliferator-activated receptor ligand-binding domain (isotype beta/delta) reveal a fatty acid in the binding site. Mass spectrometry confirmed the presence of C16:0, C16:1, C18:0 and C18:1 in a ratio of approximately 3:2:1:4 with 11, Z-octadecenoic acid (cis-vaccenic acid) identified as the predominant species. These are endogenous fatty acids acquired from the bacterial expression system, and serve to lock the ligand-binding domain into the activated conformation. A requirement for crystal growth, the additive n-heptyl-beta-(D)-glucopyranoside, binds near the activation function helix where recognition of co-activator proteins occurs. Our observations suggest potential physiological ligands for human PPAR-beta/delta and highlight that reported binding studies must be treated with caution unless endogenous fatty acids have been removed from the sample prior to analysis. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1005 / 1013
页数:9
相关论文
共 29 条
[1]   THE CCP4 SUITE - PROGRAMS FOR PROTEIN CRYSTALLOGRAPHY [J].
BAILEY, S .
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY, 1994, 50 :760-763
[2]   The mechanisms of action of PPARs [J].
Berger, J ;
Moller, DE .
ANNUAL REVIEW OF MEDICINE, 2002, 53 :409-435
[3]   PPARs: therapeutic targets for metabolic disease [J].
Berger, JP ;
Akiyama, TE ;
Meinke, PT .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2005, 26 (05) :244-251
[4]   Crystal structure of the ligand-binding domain of the ultraspiracle protein USP, the ortholog of retinoid X receptors in insects [J].
Billas, IML ;
Moulinier, L ;
Rochel, N ;
Moras, D .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (10) :7465-7474
[5]   Crystal structure of a heterodimeric complex of RAR and RXR ligand-binding domains [J].
Bourguet, W ;
Vivat, V ;
Wurtz, JM ;
Chambon, P ;
Gronemeyer, H ;
Moras, D .
MOLECULAR CELL, 2000, 5 (02) :289-298
[6]   Structure of the PPARα and -γ ligand binding domain in complex with AZ 242;: Ligand selectivity and agonist activation in the PPAR family [J].
Cronet, P ;
Petersen, JFW ;
Folmer, R ;
Blomberg, N ;
Sjöblom, K ;
Karlsson, U ;
Lindstedt, EL ;
Bamberg, K .
STRUCTURE, 2001, 9 (08) :699-706
[7]   Remarks about protein structure precision [J].
Cruickshank, DWJ .
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY, 1999, 55 :583-601
[8]   Crystal structure of the HNF4α ligand binding domain in complex with endogenous fatty acid ligand [J].
Dhe-Paganon, S ;
Duda, K ;
Iwamoto, M ;
Chi, YI ;
Shoelson, SE .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (41) :37973-37976
[9]   Synthesis and biological and structural characterization of the dual-acting peroxisome proliferator-activated receptor α/γ agonist ragaglitazar [J].
Ebdrup, S ;
Pettersson, I ;
Rasmussen, HB ;
Deussen, HJ ;
Jensen, AF ;
Mortensen, SB ;
Fleckner, J ;
Pridal, L ;
Nygaard, L ;
Sauerberg, P .
JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (08) :1306-1317
[10]   PPAR delta: an uncompletely known nuclear receptor [J].
Fredenrich, A ;
Grimaldi, PA .
DIABETES & METABOLISM, 2005, 31 (01) :23-27